10612
|
ETCTN
|
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10614
|
ETCTN
|
A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancers
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10637
|
ETCTN
|
A Phase 2 Study of Venetoclax in Relapsed Classic or Variant Hairy Cell Leukemia
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
8329
|
ETCTN
|
A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
9149
|
ETCTN
|
Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
9466
|
ETCTN
|
Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
9571
|
ETCTN
|
A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
9608
|
ETCTN
|
A Phase I Trial of ABT-263 (Navitoclax); a Bcl-2 inhibitor; and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
9653
|
ETCTN
|
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Unrothelial Carcinoma of the Bladder
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
9671
|
ETCTN
|
Exceptional Responders Pilot study: Molecular profiling of tumors from cancer patients who are Exceptional responders
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|